{"nctId":"NCT00783692","briefTitle":"Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease","startDateStruct":{"date":"2008-12"},"conditions":["Crohn's Disease"],"count":1116,"armGroups":[{"label":"Vedolizumab","type":"EXPERIMENTAL","interventionNames":["Drug: vedolizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"vedolizumab","otherNames":["Entyvio","MLN0002","MLN02","LDP-02"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18 to 80\n2. Diagnosis of moderately to severely active Crohn's disease (CD)\n3. CD involvement of the ileum and/or colon\n4. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents, within protocol-specified parameters:\n\n   1. Immunomodulators\n   2. Tumor necrosis factor-alpha (TNFα) antagonists\n   3. Corticosteroids\n5. May be receiving a therapeutic dose of conventional therapies for irritable bowel disease (IBD) defined by the protocol\n\nExclusion Criteria\n\n1. Evidence of abdominal abscess at the initial screening visit, other than a minimum of 10 aphthous ulcerations involving a minimum of 10 contiguous cm of intestine\n2. Extensive colonic resection, subtotal or total colectomy\n3. History of \\>3 small bowel resections or diagnosis of short bowel syndrome\n4. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine\n5. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol\n6. Chronic hepatitis B or C infection\n7. Active or latent tuberculosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6","description":"Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points.\n\nThe CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"14.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6","description":"Enhanced clinical response is defined as a CDAI score at least 100 points lower than Baseline. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to 600 with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"31.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52","description":"Clinical remission is defined as a CDAI score ≤ 150. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to 600 with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"39.0","spread":null},{"groupId":"OG002","value":"36.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6","description":"C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation. Normal concentration in healthy human serum is usually lower than 10 mg/L, slightly increasing with age. Higher levels indicate mild inflammation (10-40 mg/L) and active inflammation (40-200 mg/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52","description":"Enhanced clinical response is defined as a CDAI score at least 100 points lower than the Baseline value. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to 600 with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"43.5","spread":null},{"groupId":"OG002","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52","description":"Participants using oral corticosteroids at Baseline, who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 52 achieved corticosteroid-free clinical remission. The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"31.7","spread":null},{"groupId":"OG002","value":"28.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Durable Clinical Remission","description":"Durable clinical remission is defined as CDAI score ≤ 150 points at 80% or more of study visits during the Maintenance Phase, including the Week 52 visit (11 of 13 study visits). The CDAI quantifies the symptoms of patients with Crohn's disease and consists of eight factors, summed after adjustment with a weighting factor. The total score ranges from 0 to 600 with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"21.4","spread":null},{"groupId":"OG002","value":"16.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":148},"commonTop":["Arthralgia","Headache","Pyrexia","Crohn's disease","Nasopharyngitis"]}}}